New Kidney Allocation and What it Means to Your Transplant Center and Your Patients



Similar documents
*6816* 6816 CONSENT FOR DECEASED KIDNEY DONOR ORGAN OPTIONS

The New Kidney Allocation System: Resources for Protocols and Processes webinar.

Where Will my New Kidney Come From?

Questions and Answers for Transplant Candidates about the New Kidney Allocation System

Saint Francis Kidney Transplant Program Issue Date: 6/9/15

THE BENEFITS OF LIVING DONOR KIDNEY TRANSPLANTATION. feel better knowing

David Axelrod, MD, MBA. Associate Professor of Surgery Section Chief- Solid Organ Transplantation Dartmouth- Hitchcock Medical Center

Center Activity (07/01/ /30/2010) Center Region United States Tables for More Information

Deceased-Donor Renal Transplant Information for patients

Kidneys. Kidney Failure4. Transplantation

Is a kidney transplant right for me?

ANNUAL REPORT ON KIDNEY TRANSPLANTATION

User Guide. A. Program Summary B. Waiting List Information C. Transplant Information

How does a kidney transplant differ from dialysis?

Living Donor Paired Exchange Registry. What is Living Kidney Donor Paired Exchange?

LIVING KIDNEY DONATION

Renovascular Hypertension

Kidney Transplant Program. Guide to Understanding Transplant

Maintenance Steroid Avoidance in Pediatric Heart Transplantation is Associated with Excellent Graft Survival

Medicine & Emergency Department Pre-transplantation decisions and preparation

Is a Kidney Transplant Right for Me?

PANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR

Candidates about Multiple Listing and Waiting Time Transfer

Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, ESRD Registry Committee, Korean Society of Nephrology*

Expanded criteria donors for kidney transplantation

Seeking Normality: Life on the Kidney Transplant List

TA L K I N G A B O U T T R A N S P L A N TAT I O N

Kidney Disease WHAT IS KIDNEY DISEASE? TESTS TO DETECT OR DIAGNOSE KIDNEY DISEASE TREATMENT STRATEGIES FOR KIDNEY DISEASE

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working

survival, morality, & causes of death Chapter Nine introduction 152 mortality in high- & low-risk patients 154 predictors of mortality 156

Models of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK

renal transplantation: A single-center comparative study

LIVING DONATION. What You Need to Know.

Transplant Options When You Don t Have a Good Match

Kidney Transplantation

Kidney Disease: A Silent Problem

Demystifying Transplant Performance Reviews. Robyn Zernhelt Performance Analyst

The Paired Donation Network. E. Steve Woodle, M.D. Division of Transplantation University of Cincinnati

Analysis of waiting times on Irish renal transplant list

Introduction. Evaluation

Definition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013

Chapter 24: Renal Transplantation in the Older Adult

4/25/2016. Transplant Journey. Objectives. Reason for Transplantation at Mayo Clinic. Mayo Clinic Model of Care

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality

Transplant Coordinator

A07/S/a NHS STANDARD CONTRACT FOR ADULT KIDNEY TRANSPLANT SERVICE SCHEDULE 2 THE SERVICES A. SERVICE SPECIFICATIONS. Service Specification No.

Kidney Transplant Education. For the Pretransplant Patient

Patients as Partners. Kidney Care in a Holistic Perspective

John Sharp, MSSA, PMP Manager, Research Informatics Quantitative Health Sciences Cleveland Clinic, Cleveland, Ohio

What is Health Ethics?

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

Chart Number of dialysis facilities is growing, and share of for-profit and freestanding dialysis providers is increasing

The Burden Of Diabetes And The Promise Of Biomedical Research

Emory Transplant Center

Kidney and Pancreas Transplant Evaluation Clinics and Committee: Inpatient Nephrology Transplant Consult Service

End Stage Renal Disease (ESRD)

Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2003 to 2012

UCSF Kidney Transplant Symposium 2012

Comparison of the long-term outcomes of kidney transplantation: USA versus Spain

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases

June Introduction

Estimated GFR Based on Creatinine and Cystatin C

Wake Forest School of Medicine Department of General Surgery

Modifications to How New Donor Information Received Post-Transplant is Reported to Recipient Centers

Prognostic impact of uric acid in patients with stable coronary artery disease

William B. Schwartz Division of Nephrology Fellowship Training Program Curriculum

Kidney Transplantation

Facts for the Kidney Donor: Information to Consider

FAQ s ABOUT THE ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK (OPTN) KIDNEY PAIRED DONATION PILOT PROGRAM

Renal Disease in Type 2 Diabetes Mellitus

Arecent Institute of Medicine report titled Best care

Family History and Diabetes. Practical Genomics for the Public Health Professional

Donation & Transplantation

FAQ. The Kidney Project

St Lucia Diabetes and Hypertension Screening and Disease Management Programs

KIDNEY TRANSPLANTATION

NBTA report on Black, Asian and Minority Ethnic Organ Donation and Transplantation data

Kidney Pre-Transplant Patient Education Handbook. Charles O. Strickler Transplant Center

KIDNEY TRANSPLANTATION. The Most Commonly Asked Questions About Transplantation

REHABILITATION AND SOCIAL ASPECTS IN HOLISTIC APPROACH OF CKD PATIENTS

Selection of the Optimal Umbilical Cord Blood Unit

Value and Outcome Measurement in Health Care Delivery

MEDICAL POLICY. POLICY NUMBER: CATEGORY: Transplants

Organ and Tissue Donation: An Overview

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU

The Cross-Sectional Study:

Nierfunctiemeting en follow-up van chronisch nierlijden

The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C:

Type 1 Diabetes ( Juvenile Diabetes)

KIDNEY PRE-TRANSPLANT EDUCATION BOOK

ATTACHMENT I TO APPENDIX B OF UNOS BYLAWS

Where World-Class Expertise and Genuine Compassion Come Together. AT THE FOREFRONT OF TRANSPLANT CARE Kidney Combined Kidney-Pancreas Pancreas Islets

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD

Your Kidneys: Master Chemists of the Body

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes

Donating Life. The Workplace Partnership for Life Program

Diabetic Nephropathy

10/31/2014. Much is unknown. What is npod? THE JDRF Network for the Pancreatic Organ Donor with Diabetes (npod):

Transcription:

New Kidney Allocation and What it Means to Your Transplant Center and Your Patients Alexander Wiseman, M.D. Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of Colorado Health Sciences Center

The Kidney Transplant Waiting List: How do you get priority points in 2013? Time: Longest wait =1 point, with fractions of a point given for each candidate in order 1 Year=1 point Match: HLA DR match=1 point for each DR locus that is not mismatched (maximum of 2) Sensitization: Panel reactive antibody level>80%=4 points Good Samaritan: Prior kidney donation=4 points UNOS Policy 3.5

Case 1 A 24 y/o male is declared brain dead following an MVA and is an organ donor. Perfect health prior to MVA. The match run performed by UNOS identifies a recipient with the highest priority: 74 y/o man with DM, CAD s/p CABG, on dialysis/listed for 3 years, panel reactive antibody= 10% HLA DR matched at both loci=2 points 3 years of wait time=3 points Total=5 points

Case continued: #2 on the match run is a 30 yo female with IgA nephropathy on dialysis/waiting list for 3 years with a PRA of 70%, 4 Ag match (2 A, 1 B, 1 DR), listed with a different transplant program in the area HLA DR matched at one loci=1 point 3 years of wait time=3 points Total points=4 #3 on the match run is a 50 y/o with PKD, PRA 0% and no other medical problems on the waiting list for 4 years, potential 4 Ag match (2 A, 2 B) 4 years of wait time=4 points Total points=4

Major Rationale for Change The current system Uses few available objective medical criteria Kidneys with long projected post-transplant survival are allocated to candidates with short post-transplant survival (and vice versa)

Objectives for the Proposed Kidney Allocation System Improve outcomes of recipients of deceased donor kidneys through improved matching of graft/recipient projected survival Improve access for biologically disadvantaged kidney transplant candidates (highly sensitized, blood group B, minority candidates)

Overview of proposed policy Current Proposed All allocation sequences to be based on kidney donor profile index (KDPI)

Factors used to determine groups KDPI Donor age Race/ethnicity Hypertension Diabetes Serum creatinine COD CVA Height Weight DCD HCV Candidate Estimated Post-Transplant Survival (EPTS) Candidate Age Candidate Diabetes Prior transplant ESRD time

Overview of proposed policy Proposed Allocation to those with longest expected posttransplant survival Allocation first to Pediatric list, then according to waiting time Allocation according to waiting time Allocation to those who consent (similar to today s ECD ) All allocation sequences to be based on kidney donor profile index (KDPI)

Kidney Donor Profile Index (KDPI) KDPI Variables Donor age Height Weight Ethnicity History of Hypertension History of Diabetes Cause of Death Serum Creatinine HCV Status DCD Status

Case (for the referring nephrologist): Your 55 yo patient with T2DM, not yet on dialysis (but is close, with GFR 13) has consented to a KDPI >85. He gets an offer for a kidney that has KDPI of >85. Do you: A. Advise him to take it B. Advise him to decline it C. Ask about the KDPI

Case (for the transplant center): You receive an offer for a 55 yo patient with T2DM, not yet on dialysis (but is close, with GFR 13) who has consented to a KDPI >85. The donor is a 59 yo obese AA with CVA and HTN. The KDPI is 95. Do you: A. Accept the kidney B. Decline the kidney

Highly sensitized patients rarely get offers under current allocation policy

New Policy: Sensitization Points (Current) (Proposed) Current policy awards 4 points to candidates with PRA>80% Candidates <80% do not receive any points Proposed policy would generate a sliding scale for priority so that highly sensitized candidates get improved access

Modeling transplant results by CPRA (95-100%)

Projected results >8000 additional life years annually Slight increase in transplants to African Americans, blood type B, and high PRA recipients % of transplants 45 40 35 30 25 20 15 current estimated Changes in age distribution 10 5 0 <18 18-34 35-49 50-64 65+ Recipients, by age

Allocation Scheme

Scenario 1: 48 yo with FSGS on HD for 7 years, variably adherent, missed transplant evaluations x 2 in past (illness). Still modestly nonadherent. Makes appointment, is ultimately placed on waiting list. Scenario 2: 68 yo with DM on HD for 2 years, very adherent, missed transplant evaluation in past (illness). Still very functional on CCPD, is ultimately placed on waiting list.

Proposed Point Changes: Waiting Time Current policy begins waiting time points for adults at registration with: GFR<=20 ml/min Dialysis time Proposed policy would also award waiting time points for dialysis time prior to registration Applies to both pediatric and adult candidates Better recognizes time spent with ESRD as the basis for priority Pre-emptive listing would still be advantageous for 0-ABDR mismatch offers

Discussion For the physician: How do you educate patients regarding new allocation policies? For the transplant center: How do you manage the waiting list with the new allocation policies?

Conclusions KDPI will permit efficient allocation but does not necessarily increase number of transplants, unless demand for high KDPI increases Sliding scale for sensitization/%pra are components that have gained approval

Case A 17 yo patient with Henoch-Schonlein Purpura (HSP) and CKD V not yet on dialysis She has a family member who is interested in donating with compatible blood type. Average waiting time for an adult blood type O candidate is 5 years What is the likelihood that she will get an offer for a kidney within 2 months? 12 months? What do you recommend: A) living donor transplant B) wait for deceased donor transplant

Pediatric Kidney Allocation

Pediatric kidney transplantation With introduction of Share 35 in November 2005 (in which all deceased donors < 35y are offered first to candidates <18y), waiting time is shorter, rates of living donation have fallen Age at 2002 2003 2004 2005 2006 2007 Registration <1 Year 65 238 189 346 283 + 1-5 Years 195 241 227 242 210 304 6-11 Years 369 389 240 321 217 216 12-17 Years 478 471 368 272 201 239 18-34 Years 972 957 971 1055 + + Is shortening pediatric waiting time by 2-4 months really the best strategy? SRTR Annual Report 2011 Fig 8.13

Inferior outcomes with deceased donor vs living donor in pediatric recipients Higher acute rejection rates Worse graft survival Is the shorter waiting time worth the de-emphasis on living donation? SRTR Annual Report 2011 Figs 8.26, 8.27

Utility of Share 35 donor kidneys are NOT optimized by use in pediatric population Using Share 35 donors, overall graft survival and deathcensored graft survival is better in adults than those 17 Higher graft loss in younger recipients Higher death rate in older recipients Best utility is in recipients age 31-45, not the pediatric recipients Moudgil A et al, Transplantation 2013; 95:319

Pancreas Allocation and Transplantation

Patients receiving SPK transplants have the greatest net lifetime benefit * from transplantation *(estimated survival with functioning graft) - (estimated survival on dialysis x 0.8) 4% 32% 64% Wolfe R et al, AJT 2008; 8: 997-1011

Organ Allocation: The kidney follows the pancreas Organ Donor: 2 kidneys, 1 pancreas Pancreas list A (E on kidney list) B C (G on kidney list) D Kidney list A B C D E F G If Pancreas follows kidney : Candidates A and B get kidneys, and B gets panc If Kidney follows pancreas : Candidate A gets kidney, and E gets SPK INCENTIVE TO PUT PATIENTS ON SPK LIST (EVEN T2DM???)

Organ Allocation for Diabetes: The kidney follows the pancreas Median waiting time to transplant (days) 2004 SPK A: 323 B: 520 O: 533 AB:214 Kidney A: 815 B: 1655 O: 1568 AB: 602 INCENTIVE TO PUT PATIENTS ON SPK LIST (EVEN T2DM???) SRTR Annual Report 2009

Case 46 yo man with T1DM who underwent SPK transplant after only 14 months of waiting tells his buddy with T2DM on dialysis how great it is to be off dialysis and without insulin. His buddy, a 49 yo with BMI 29, has been waiting on the kidney transplant waiting list for 2 years and wonders if he can undergo an SPK transplant What do you advise him? A) He is not a candidate due to T2DM B) SPK is much less successful in T2DM than T1DM C) SPK may be a reasonable option

Simultaneous Pancreas Kidney Transplantation: For T2DM? In U.S.-Eligibility for SPK waiting list: 1. DM with c-peptide <2 ng/ml 2. DM, c-peptide >2 ng/ml with BMI <28-30kg/m 2

Pancreas transplant outcomes are equivalent in T1DM vs. selected T2DM OPTN/UNOS Data analysis of SPK recipients 2000-2007 582 T2DM recipients vs 6141 T1DM recipients Patient Survival Pancreas Graft Survival Pancreas-related complications T1DM T2DM P One-year kidney and/or pancreas rejection 15.8 14.7 0.89 Pancreas complications abscess/local infection 4.37 2.95 0.23 anastomosis leak 2.15 1.91 0.91 pancreatitis 2.43 1.56 0.42 primary nonfunction 0.86 0.86 0.75 surgery to convert bladder to enteric drainage 1.43 1.37 0.91 Sampiao M et al, CJASN 2011; 6: 1198

Does the added pancreas transplant lead to better outcomes for young, thin patients with T2DM? SRTR analysis of patients with T2DM, age 18-59, with BMI 18-30 kg/m 2 receiving an SPK (n=424), LDKA or DDKA during 2000-2008: Multivariate analysis: HR 0.9 (p=ns) Multivariate analysis: HR 0.5 (p<0.001)) SPK: better patient survival than DDKA, but inferior compared to LDKA SPK: Waiting time much shorter, donor age much younger than DDKA Wiseman AC and Gralla J, CJASN 2012 Apr;7(4):656

Summary/Conclusion: SPK as a Transplant Option Avoid dialysis know the waiting time expectations for SPK and advise your patients accordingly For most T1DM: SPK is preferable to deceased donor kidney transplant. LD kidney transplant vs SPK: depends on dialysis/waiting time For most T2DM: LD > DD <10% of T2DM may be eligible for SPK, better than DD but may be inferior to LD